2-[(2-oxopropyl)thio] imidazolium derivates

This class of non-peptidyl, active site directed molecules was developed by Merck Sharp & Dohme in the 1990s. The active site cysteinyl residue attacks the carbonyl group (1) similar to the glutamine residue. However, the subsequent reaction leads to the release of the complementary thione (2) and to the acetonylation of the cysteine (3) (Freund et al., Biochemistry 1994, 33:10109-19).

Even if the molecules were developed to block coagulation factor XIIIa, the compounds inhibit tissue transglutaminase as well (Barsigan et al., J. Biol. Chem. 1991, 22501-9).

One candidate out of the series has been evaluated in animal models (e.g. Shebuski et al., blood 1990, 1455-9). Please notice that the authors reported a plasma half life of 5 to 10 minutes only.

Oxopropyl thio imidazolium derivates mechanism

Zedira offers three derivatives of the thioimidazolium scaffold.

  • T101 (L-682.777) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are inhibited with an IC50 of about 0.25 μM.
  • D004 (L-683.685) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are blocked with an IC50 of about 0.35 μM.
  • D003 is a weak blocker of tissue transglutaminase with an IC50 of about 1.0 μM.

Art. No.
D003 1,3-Dimethyl-2-[(2-oxopropyl)thio]imidazolium chloride
100 mg
480 €
D004 1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt
10 mg
520 €
T101 1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride
10 mg
480 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy